Business Update - Manufacturing commences
Released
Released
Announcement PDF
®
IMAGION BIOSYSTEMS LIMITED
(ASX: IBX)
26 February 2020
Business Update: Manufacturing commences
MELBOURNE – Imagion Biosystems Limited (ASX: IBX) (the Company), a company dedicated
to improving healthcare through the earlier detection of cancer, is pleased to provide an update on
progress towards its key business objective of initiating its first study for HER2 metastatic breast
cancer in human subjects this year.
The primary operational focus for the past quarter has been on ensuring the readiness of its
contract-manufacturing partners to begin the manufacturing of the nanoparticle formulation to be
used in the study. The company is pleased to report it has purchased equipment and supplies and
has completed the necessary vendor qualifications and audits to confirm compliance with GMP
(Good Manufacturing Practice), required for the manufacturing of medical devices and
pharmaceutical products used in human clinical studies.
With these steps complete, the company will now commence manufacturing.
“Patient safety is of paramount importance for all human studies,” said Bob Proulx, Executive
Chairman of Imagion Biosystems. “With this being the first time our nanoparticle product is to be
used in a human study, we have taken great care in our preparations to ensure we could move
forward with confidence into manufacturing and achieve the exacting standards required of GMP
manufacturing processes.”
While manufacturing proceeds, the Company will continue working on the other key areas
needed to support initiating the study later this year when manufacturing is complete. This
includes establishing clinical sites and preparing the sites for enrolment of subjects, and
receiving the necessary regulatory authorization, for example an Investigational Device
Exemption (IDE) from the US FDA.
Dialogue with the FDA continues as previously advised, and is in line with expectations at this
stage of the process.
- ENDS
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other
diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed
on the Australian Securities Exchange (ASX) in June 2017.
This Announcement has been approved by the Disclosure Committee of Imagion Biosystems
Limited
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology.
Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
®
earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian
Securities Exchange (ASX) in June 2017.
This Announcement has been approved by the Disclosure Committee of Imagion Biosystems
Limited
For further information please visit www.imagionbiosystems.com
U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630
Australian Media & Investor Relations:
Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722
Imagion Biosystems Limited
ACN 616 305 027
Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystem.com
Share your feedback
Discover